Can endocan be a new biomarker in ventilator‐associated pneumonia?

Küpeli, İlke; Salcan, Sara; Kuzucu, Mehmet; Kuyrukluyıldız, Ufuk

doi:10.1016/j.kjms.2018.07.002

Cited by 9 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18 It has been determined that serum endocan levels are increased in ventilator-associated pneumonia, which is an important cause of mortality in adult intensive care units. 19 All these studies supported the hypothesis of rapid release of endocan from the lung epithelium with other cytokines in the early stages of pneumonia.…”

Section: Discussionsupporting

confidence: 65%

Is Serum Endocan Level an Indicator of the Severity of Childhood Community-Acquired Pneumonia?

Bozkurt

Abdullah

Ergüven

2022

J Pediatr Infect Dis

View full text Add to dashboard Cite

Objective We aimed to investigate the relationship between serum endocan, procalcitonin (PCT), C-reactive protein (CRP), white blood cell count (WBC), neutrophil/lymphocyte ratios (NLR), and the severity of the disease in childhood community-acquired pneumonia (CAP) cases. Methods This cross-sectional designed study included 30 pneumonia cases and 30 severe pneumonia cases aged between 3 months and 18 years who were hospitalized and treated in our hospital with the diagnosis of CAP. We also included 30 healthy controls in the same age range. Pearson's correlation and receiver operating characteristic (ROC) curve analyzes were performed. Results PCT, endocan, NLR, and CRP levels were found to be significantly higher in patients with severe pneumonia. Sensitivity and specificity values in detecting pneumonia were 72.5 and 93% for PCT, 78.4 and 83.3% for CRP, 78.4 and 76.7% for endocan, and 64.7 and 63.3% for NLR. However, the area under the curve in ROC analysis were 0.821, 0.840, 0.842, and 0.670 for PCT, CRP, endocan, and NLR respectively. Conclusion Endocan may be a marker of the diagnosis of pneumonia and not clinical severity, but studies are needed in large patient populations.

show abstract

Section: Discussionsupporting

confidence: 65%

Is Serum Endocan Level an Indicator of the Severity of Childhood Community-Acquired Pneumonia?

Bozkurt

Abdullah

Ergüven

2022

J Pediatr Infect Dis

View full text Add to dashboard Cite

show abstract

“…The binding of ESM-1 to LFA1 inhibited the specific binding of ICAM-1 to Jurkat cells, implying that ESM1 could regulate LFA-1/ICAM-1 pathway and thus suppress lymphocyte recruitment to inflammatory sites and activation [19]. However, in vivo experiments and clinical data both supported that ESM1 promotes inflammatory and account for inflammatory related disease including ventilator associated pneumonia [28], cardiovascular disease [29], and sepsis [30]. By using Esm1 knockout mice Susana F. Rocha et al showed that Esm1 does not affect leukocyte rolling and adhesion in vivo, but positively regulates leukocyte extravasation at the endothelial transmigration level [31].…”

Section: Discussionmentioning

confidence: 99%

B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibition tumor infiltrating CD4+T cell cytotoxicity through ESM1

Qian,

li,

Feng

et al. 2023

Preprint

View full text Add to dashboard Cite

Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4+T cells but not CD8+T cells are the main lymphocyte population suppressed by Bcl6 to promote HCC development. Mechanistically, BCL6 decreases cancer cell expression of pro-inflammatory cytokines and T lymphocyte chemokines such as IL6, IL1F6, and CCL5. Moreover, BCL6 upregulates Endothelial cell-specific molecule 1 (ESM1) to inhibit T lymphocyte recruitment and activation possibly through ICAM-1/LFA-1 signaling pathway. Our findings uncovered an unappreciated paracrine mechanism how cancer cell derived BCL6 assists cancer cell immune evasion, and highlighted the role of CD4+T cells in HCC immune surveillance.

show abstract

“…High endocan levels have been reported in patients with ventilator-associated pneumonia (VAP). Elevated endocan levels have been linked to the development of VAP, and that this can be used as a screening test ( 19 ). Another study reported increased serum endocan levels in severe sepsis patients requiring mechanical ventilation in the intensive care unit.…”

Section: Discussionmentioning

confidence: 99%

Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR

Laloğlu

Alay

2022

ujms

View full text Add to dashboard Cite

Background: Endothelial-specific molecule 1 (endocan) has emerged as an inflammatory biomarker in recent years. The purpose of this study was to investigate the diagnostic value of serum endocan levels in the prediction of COVID-19 disease among patients with a false-negative reverse transcription polymerase change reaction (RT-PCR) test, and also to determine its correlation with the clinical severity of the disease. Methods: Thirty patients with positive RT-PCR results and 30 with false-negative RT-PCR results, both with suspected COVID-19 in terms of clinical, radiological, and laboratory findings, were included in the study. Thirty healthy controls were also enrolled. Results: Serum endocan levels were estimated to be 821.8 ± 99.3 pg/mL in COVID-19 RT-PCR (+) patients, 803.9 ± 97.0 pg/mL in RT-PCR false (–) patients with suspected COVID-19, and 382.9 ± 37.5 pg/mL in the control group. No significant difference was observed between RT-PCR (+) and RT-PCR false (–) patients (P = 0.68). However, serum endocan levels differed significantly between patient groups and control group (P < 0.05). With a cut-off value of 444.2 pg/mL serum endocan levels differentiated COVID-19 cases from healthy individuals with 92% sensitivity and 80% specificity. Moreover, a significant positive correlation was observed between serum endocan levels and clinical severity (P < 0.01, r = 0.94). Conclusions: There is a need for different laboratory markers capable of assisting diagnosis and showing COVID-19 infection in suspected COVID-19 RT-PCR false-negative patients. Endocan levels can be used as an assistant blood test for identifying COVID-19 patients with false-negative RT-PCR tests and in determining the clinical severity of the disease.

show abstract

Can endocan be a new biomarker in ventilator‐associated pneumonia?

Cited by 9 publications

References 27 publications

Is Serum Endocan Level an Indicator of the Severity of Childhood Community-Acquired Pneumonia?

Is Serum Endocan Level an Indicator of the Severity of Childhood Community-Acquired Pneumonia?

B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibition tumor infiltrating CD4+T cell cytotoxicity through ESM1

Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR

Contact Info

Product

Resources

About